Published Date：Mar.2021
Industry：Pharma & Healthcare
Pages：100 Table Number：124
Single User Price：￥3650.00
Enterprise User Price：￥5600.00
Summary As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%. Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States. In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter. Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970. Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Multiple Sclerosis (MS) market in this environment. In terms of revenue, this research report indicated that the global Multiple Sclerosis (MS) market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Multiple Sclerosis (MS) industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments. The Biogen Idec aims at producing XX K Units Multiple Sclerosis (MS) in 2020, with XX % production to take place in global market, Novartis accounts for a volume share of XX %. Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Multiple Sclerosis (MS) Market by XYZResearch Include China EU USA Japan India Southeast Asia South America Competitive Analysis; Who are the Major Players in Multiple Sclerosis (MS) Market? Biogen Idec Novartis EMD Serono Sanofi Teva Pharmaceutical Bayer Pfizer Synthetic Biologic Active Biotech Opexa ... Major Type of Multiple Sclerosis (MS) Covered in XYZResearch report: Relapsing–Remitting Multiple Sclerosis (RRMS) Secondary Progressive Multiple Sclerosis (SPMS) Primary Progressive Multiple Sclerosis (PPMS) Rapidly Evolving Severe relapsing–remitting multiple sclerosis (RES) Application Segments Covered in XYZResearch Market Injectable agents Oral agents Application 3 For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents Global Multiple Sclerosis (MS) Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate 1 Market Scope 1.1 Product Details and Introduction 1.1.1 Relapsing–Remitting Multiple Sclerosis (RRMS) -Product Introduction and Major Manufacturers 1.1.2 Secondary Progressive Multiple Sclerosis (SPMS) -Product Introduction and Major Manufacturers 1.1.3 Primary Progressive Multiple Sclerosis (PPMS) -Product Introduction and Major Manufacturers 1.1.4 Rapidly Evolving Severe relapsing–remitting multiple sclerosis (RES) -Product Introduction and Major Manufacturers 1.2 Market Snapshot 1.2.1 Major Companies Overview 1.2.2 Market Concentration 1.2.3 Six-Year Compound Annual Growth Rate (CAGR) 2 Global Multiple Sclerosis (MS) Market Assessment, by Segmentation 2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027) 2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027) 2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027) 3 Regional Market Analysis 3.1 China Multiple Sclerosis (MS) Market 3.1.1 Top Companies leading Multiple Sclerosis (MS) Development in China (2016-2021) 3.1.2 Sales Value of Major Company in China Market (2016-2021) 3.1.3 China Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) 3.1.4 Sales in China Market, by Type (2026-2027) 3.2 EU Multiple Sclerosis (MS) Market 3.2.1 Top Companies leading Multiple Sclerosis (MS) Development in EU (2016-2021) 3.2.2 Sales Value of Major Company in EU Market (2016-2021) 3.2.3 EU Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) 3.2.4 Sales in EU Market, by Type (2026-2027) 3.3 USA Multiple Sclerosis (MS) Market 3.3.1 Top Companies leading Multiple Sclerosis (MS) Development in USA (2016-2021) 3.3.2 Sales Value of Major Company in USA Market (2016-2021) 3.3.3 USA Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) 3.3.4 Sales in USA Market, by Type (2026-2027) 3.4 Japan Multiple Sclerosis (MS) Market 3.4.1 Top Companies leading Multiple Sclerosis (MS) Development in Japan (2016-2021) 3.4.2 Sales Value of Major Company in Japan Market (2016-2021) 3.4.3 Japan Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) 3.4.4 Sales in Japan Market, by Type (2026-2027) 3.5 India Multiple Sclerosis (MS) Market 3.5.1 Top Companies leading Multiple Sclerosis (MS) Development in India (2016-2021) 3.5.2 Sales Value of Major Company in India Market (2016-2021) 3.5.3 India Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) 3.5.4 Sales in India Market, by Type (2026-2027) 3.6 Southeast Asia Multiple Sclerosis (MS) Market 3.6.1 Top Companies leading Multiple Sclerosis (MS) Development in Southeast Asia (2016-2021) 3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021) 3.6.3 Southeast Asia Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) 3.6.4 Sales in Southeast Asia Market, by Type (2026-2027) 3.7 South America Multiple Sclerosis (MS) Market 3.7.1 Top Companies leading Multiple Sclerosis (MS) Development in South America (2016-2021) 3.7.2 Sales Value of Major Company in South America Market (2016-2021) 3.7.3 South America Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) 3.7.4 Sales in South America Market, by Type (2026-2027) 4 Value Chain (Impact of COVID-19) 4.1 Multiple Sclerosis (MS) Value Chain Analysis 4.1.1 Upstream 4.1.2 Downstream 4.2 COVID-19 Impact on Multiple Sclerosis (MS) Industry 4.2.1 Industrial Policy Issued Under the Epidemic Situation 4.3 Cost-Under the Epidemic Situation 4.3.1 Cost of Raw Material 4.4 Channel Analysis 4.4.1 Distribution Channel-Under the Epidemic Situation 4.4.2 Distributors 5 Regional Market Forecast (2021-2027) 5.1 Global Multiple Sclerosis (MS) Sales and Growth Rate (2021-2027) 5.2 Global Multiple Sclerosis (MS) Sales Value and Growth Rate (2021-2027) 6 Multiple Sclerosis (MS) Competitive Analysis 6.1 Biogen Idec 6.1.1 Biogen Idec Company Profiles 6.1.2 Biogen Idec Product Introduction 6.1.3 Biogen Idec Multiple Sclerosis (MS) Production, Revenue (2016-2021) 6.1.4 SWOT Analysis 6.2 Novartis 6.2.1 Novartis Company Profiles 6.2.2 Novartis Product Introduction 6.2.3 Novartis Multiple Sclerosis (MS) Production, Revenue (2016-2021) 6.2.4 SWOT Analysis 6.3 EMD Serono 6.3.1 EMD Serono Company Profiles 6.3.2 EMD Serono Product Introduction 6.3.3 EMD Serono Multiple Sclerosis (MS) Production, Revenue (2016-2021) 6.3.4 SWOT Analysis 6.4 Sanofi 6.4.1 Sanofi Company Profiles 6.4.2 Sanofi Product Introduction 6.4.3 Sanofi Multiple Sclerosis (MS) Production, Revenue (2016-2021) 6.4.4 SWOT Analysis 6.5 Teva Pharmaceutical 6.5.1 Teva Pharmaceutical Company Profiles 6.5.2 Teva Pharmaceutical Product Introduction 6.5.3 Teva Pharmaceutical Multiple Sclerosis (MS) Production, Revenue (2016-2021) 6.5.4 SWOT Analysis 6.6 Bayer 6.6.1 Bayer Company Profiles 6.6.2 Bayer Product Introduction 6.6.3 Bayer Multiple Sclerosis (MS) Production, Revenue (2016-2021) 6.6.4 SWOT Analysis 6.7 Pfizer 6.7.1 Pfizer Company Profiles 6.7.2 Pfizer Product Introduction 6.7.3 Pfizer Multiple Sclerosis (MS) Production, Revenue (2016-2021) 6.7.4 SWOT Analysis 6.8 Synthetic Biologic 6.8.1 Synthetic Biologic Company Profiles 6.8.2 Synthetic Biologic Product Introduction 6.8.3 Synthetic Biologic Multiple Sclerosis (MS) Production, Revenue (2016-2021) 6.8.4 SWOT Analysis 6.9 Active Biotech 6.9.1 Active Biotech Company Profiles 6.9.2 Active Biotech Product Introduction 6.9.3 Active Biotech Multiple Sclerosis (MS) Production, Revenue (2016-2021) 6.9.4 SWOT Analysis 6.10 Opexa 6.10.1 Opexa Company Profiles 6.10.2 Opexa Product Introduction 6.10.3 Opexa Multiple Sclerosis (MS) Production, Revenue (2016-2021) 6.10.4 SWOT Analysis 7 Conclusion
List of Tables and Figures Figure Product Introduction Table Production (K Units) and Revenue (Million USD) of Major Players (2016-2021) Figure Global Multiple Sclerosis (MS) Production Market Share of Top 5 Players Table CAGR of Major Market (2021-2027) Table CAGR in Terms of Production of Each Type (2026-2027) Table CAGR in Terms of Production of Each Application (2026-2027) Table Global Multiple Sclerosis (MS) Sales (K Unit) by Type (2026-2027) Figure Global Multiple Sclerosis (MS) Sales (K Unit) and Growth Rate (2026-2027) Figure Global Multiple Sclerosis (MS) Sales Market Share (%) by Type (2019 -2020) Table Global Multiple Sclerosis (MS) Sales Value (Million USD) by Type (2026-2027) Figure Global Multiple Sclerosis (MS) Sales Value (Million USD) and Growth Rate (2026-2027) Figure Global Multiple Sclerosis (MS) Sales Value Market Share (%) by Type (2019-2020) Table Global Multiple Sclerosis (MS) Sales (K Unit) by Application (2026-2027) Table China Multiple Sclerosis (MS) Sales (K Unit) of Major Company (2016-2021) Table China Multiple Sclerosis (MS) Sales Market Share of Major Company (2016-2021) Table China Multiple Sclerosis (MS) Sales Value (Million USD) of Major Company (2016-2021) Figure China Multiple Sclerosis (MS) Sales Value (Million USD) and Growth Rate (2016-2021) Table China Multiple Sclerosis (MS) Sales Value Share of Major Company (2016-2021) Table China Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) Table China Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Figure China Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Table EU Multiple Sclerosis (MS) Sales (K Unit) of Major Company (2016-2021) Table EU Multiple Sclerosis (MS) Sales Market Share of Major Company (2016-2021) Table EU Multiple Sclerosis (MS) Sales Value (Million USD) of Major Company (2016-2021) Figure EU Multiple Sclerosis (MS) Sales Value (Million USD) and Growth Rate (2016-2021) Table EU Multiple Sclerosis (MS) Sales Value Share of Major Company (2016-2021) Table EU Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) Table EU Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Figure EU Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Table USA Multiple Sclerosis (MS) Sales (K Unit) of Major Company (2016-2021) Table USA Multiple Sclerosis (MS) Sales Market Share of Major Company (2016-2021) Table USA Multiple Sclerosis (MS) Sales Value (Million USD) of Major Company (2016-2021) Figure USA Multiple Sclerosis (MS) Sales Value (Million USD) and Growth Rate (2016-2021) Table USA Multiple Sclerosis (MS) Sales Value Share of Major Company (2016-2021) Table USA Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) Table USA Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Figure USA Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Table Japan Multiple Sclerosis (MS) Sales (K Unit) of Major Company (2016-2021) Table Japan Multiple Sclerosis (MS) Sales Market Share of Major Company (2016-2021) Table Japan Multiple Sclerosis (MS) Sales Value (Million USD) of Major Company (2016-2021) Figure Japan Multiple Sclerosis (MS) Sales Value (Million USD) and Growth Rate (2016-2021) Table Japan Multiple Sclerosis (MS) Sales Value Share of Major Company (2016-2021) Table Japan Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) Table Japan Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Figure Japan Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Table India Multiple Sclerosis (MS) Sales (K Unit) of Major Company (2016-2021) Table India Multiple Sclerosis (MS) Sales Market Share of Major Company (2016-2021) Table India Multiple Sclerosis (MS) Sales Value (Million USD) of Major Company (2016-2021) Figure India Multiple Sclerosis (MS) Sales Value (Million USD) and Growth Rate (2016-2021) Table India Multiple Sclerosis (MS) Sales Value Share of Major Company (2016-2021) Table India Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) Table India Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Figure India Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Table Southeast Asia Multiple Sclerosis (MS) Sales (K Unit) of Major Company (2016-2021) Table Southeast Asia Multiple Sclerosis (MS) Sales Market Share of Major Company (2016-2021) Table Southeast Asia Multiple Sclerosis (MS) Sales Value (Million USD) of Major Company (2016-2021) Figure Southeast Asia Multiple Sclerosis (MS) Sales Value (Million USD) and Growth Rate (2016-2021) Table Southeast Asia Multiple Sclerosis (MS) Sales Value Share of Major Company (2016-2021) Table Southeast Asia Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) Table Southeast Asia Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Figure Southeast Asia Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Table South America Multiple Sclerosis (MS) Sales (K Unit) of Major Company (2016-2021) Table South America Multiple Sclerosis (MS) Sales Market Share of Major Company (2016-2021) Table South America Multiple Sclerosis (MS) Sales Value (Million USD) of Major Company (2016-2021) Figure South America Multiple Sclerosis (MS) Sales Value (Million USD) and Growth Rate (2016-2021) Table South America Multiple Sclerosis (MS) Sales Value Share of Major Company (2016-2021) Table South America Multiple Sclerosis (MS) Price (USD/Unit), by Type (2019-2020) Table South America Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Figure South America Multiple Sclerosis (MS) Sales (Unit) by Type (2026-2027) Figure Value Chain Structure of Multiple Sclerosis (MS) Table Value Chain Table Key Suppliers of Raw Material/Components Table Key Downstream Customer in Each Application Field Table Industry News List of Multiple Sclerosis (MS) Figure Cost Structure of Multiple Sclerosis (MS) in 2020 Table Distributors/Traders List Table Regional Market Sales (K Unit) (2021-2027) Table Regional Market Sales Share (2021-2027) Figure Global Multiple Sclerosis (MS) Sales (Unit), Growth Rate & Market Share (2021-2027) Table Regional Market Sales Value (Million USD) (2021-2027) Table Regional Market Sales Value Share (2021-2027) Figure Global Multiple Sclerosis (MS) Sales Value (Million USD), Growth Rate & Market Share (2021-2027) Table Biogen Idec Profiles Table Biogen Idec Multiple Sclerosis (MS) Product Introduction Table Biogen Idec Multiple Sclerosis (MS) Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure Biogen Idec SWOT Analysis Table Novartis Profiles Table Novartis Multiple Sclerosis (MS) Product Introduction Table Novartis Multiple Sclerosis (MS) Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure Novartis SWOT Analysis Table EMD Serono Profiles Table EMD Serono Multiple Sclerosis (MS) Product Introduction Table EMD Serono Multiple Sclerosis (MS) Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure EMD Serono SWOT Analysis Table Sanofi Profiles Table Sanofi Multiple Sclerosis (MS) Product Introduction Table Sanofi Multiple Sclerosis (MS) Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure Sanofi SWOT Analysis Table Teva Pharmaceutical Profiles Table Teva Pharmaceutical Multiple Sclerosis (MS) Product Introduction Table Teva Pharmaceutical Multiple Sclerosis (MS) Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure Teva Pharmaceutical SWOT Analysis Table Bayer Profiles Table Bayer Multiple Sclerosis (MS) Product Introduction Table Bayer Multiple Sclerosis (MS) Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure Bayer SWOT Analysis Table Pfizer Profiles Table Pfizer Multiple Sclerosis (MS) Product Introduction Table Pfizer Multiple Sclerosis (MS) Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure Pfizer SWOT Analysis Table Synthetic Biologic Profiles Table Synthetic Biologic Multiple Sclerosis (MS) Product Introduction Table Synthetic Biologic Multiple Sclerosis (MS) Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure Synthetic Biologic SWOT Analysis Table Active Biotech Profiles Table Active Biotech Multiple Sclerosis (MS) Product Introduction Table Active Biotech Multiple Sclerosis (MS) Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021) Figure Active Biotech SWOT Analysis Table Opexa Profiles Table Opexa Multiple Sclerosis (MS) Product Introduction Table Opexa Multiple Sclerosis (MS) Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2016-2021)
